India's Ranbaxy
gets US FDA nod to manufacture, market generic of
GSK's Ceftin
Posted Atmoney.cnn.com
BANGALORE, Feb. 6, 2008 (Thomson
Financial delivered by Newstex) -- India's Ranbaxy
Laboratories Ltd said its US unit has received US
FDA approval to manufacture and market the generic
version of GlaxoSmithKline PLC's (NYSE:GSK) paediatric
anti-bacterial drug Ceftin, Cefuroxime Axetil, for
oral suspension in the 125mg/5ml and 250mg/5ml dosage
form.
The pharma major said the
total annual market sales for Cefuroxime Axetil Suspension
were 28.7 mln usd as per IMS Health (NYSE:RX) data,
December 2007.
Jim Meehan, vice president
of sales and distribution for Ranbaxy's US unit, said:
'Ranbaxy is pleased to receive this approval for Cefuroxime
Axetil Suspension that now allows us to be the only
generic company to offer both dosage forms for a product
that is highly prescribed.'
Copyright Thomson Financial
News Limited 2007. All rights reserved.
The copying, republication
or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly
prohibited without the prior written consent of Thomson
Financial News.
February 06, 2008 |
